Lepola, Ulla

Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology

Treatment of Major DepressionMental Health Treatment and Access

Cited by 254

CSF corticotropin-releasing factor is not affected in panic disorder

Jolkkonen, J., Lepola, U., Bissette, G., Nemeroff, C., & Riekkinen, P. (1993) · Biological Psychiatry

Stress Responses and CortisolAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 49

Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant

Vieta, E., Thase, M. E., Naber, D., D’Souza, B., Rancans, E., Lepola, U., Olausson, B., Szamosi, J., Wilson, E., Hosford, D., et al. (2014) · European Neuropsychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 43

Sleep in panic disorders

Lepola, U., Koponen, H., & Leinonen, E. (1994) · Journal of Psychosomatic Research

Sleep and related disordersAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 39

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study

Lepola, U., Hefting, N., Zhang, D., & Hobart, M. (2018) · International Journal of Geriatric Psychiatry

Treatment of Major DepressionSchizophrenia research and treatment

Cited by 15